MedTrace Logo

Study of the Gut Hormone Analogue G3215 in Adult Subjects

NCT02692040 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-12-23

Study results available
· View outcomes & findings →

Summary

A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.

Conditions

Interventions

DRUG

G3215

Gut hormone analogue

DRUG

Placebo

0.9% saline

Sponsors & Collaborators

Principal Investigators

  • Jim Bush, PhD MRCS · Covance Clinical Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02692040 on ClinicalTrials.gov